Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University | OTHER |
| Samta Ayurveda Prakoshtha, India | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19.
With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear.
Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ayurveda | Guduchi Ghan Vati was given to Covid patients 2 tablets (500 mg each) twice daily were given orally after meal for 28 days. Guduchi ghan vati is a powdered aqueous extract of Tinospora cordifolia in tablet form and prepared in GMP certified Pharmacy of the University, following standard protocol. |
| |
| Control | Standard care for asymptomatic confirmed cases is isolation (to contain virus transmission) and clinical monitoring as per recommended Guidelines. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Guduchi Ghan Vati | Drug | Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Virologic clearance | Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result | 21 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the number of patients going from asymptomatic to moderately disease | change in the number of patients going from asymptomatic to moderately disease | 10-days of hospital admission |
| Hospital Stay |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Covid-19 Confirmed Asymptomatic patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Parashar Sharma | Samta Ayurveda Prakoshtha | Study Chair |
| Jaydeep Joshi | Aarogyam UK | Study Chair |
| Neha Sharma | Aarogyam UK | Study Director |
| Abhimanyu Kumar | Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University | Jodhpur | Rajasthan | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D058070 | Asymptomatic Diseases |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Total duration of stay in hospital for complete recovery
| 21 days |
| Clinically relevant adverse effects | Clinically relevant adverse effects of Guduchi Ghan Vati (Disability, Discomfort reported) | 21-days |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |